Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior t1 MAb a possible new approach to treat this disease.

Literature DB >> 10433078

CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior t1 MAb a possible new approach to treat this disease.

E Montero, L Falcon, Y Morera, J Delgado, J F Amador, R Perez.

Abstract

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1999 PMID： 10433078 DOI： 10.3109/08916939908995386

Source DB: PubMed Journal: Autoimmunity ISSN： 0891-6934 Impact factor: 2.815

Keyword Cloud
Cited

× No keyword cloud information.

9 in total

1. CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction.

Authors: P Nair; R Melarkode; D Rajkumar; E Montero
Journal: Clin Exp Immunol Date: 2010-08-19 Impact factor: 4.330

2. Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab).

Authors: Christelle Le Dantec; Ruby Alonso; Tinhinane Fali; Enrique Montero; Valérie Devauchelle; Alain Saraux; Jacques-Olivier Pers; Yves Renaudineau
Journal: Immunol Res Date: 2013-07 Impact factor: 2.829

3. The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.

Authors: P C Rodríguez; D M Prada; E Moreno; L E Aira; C Molinero; A M López; J A Gómez; I M Hernández; J P Martínez; Y Reyes; J M Milera; M V Hernández; R Torres; Y Avila; Y Barrese; C Viada; E Montero; P Hernández
Journal: Clin Exp Immunol Date: 2017-11-16 Impact factor: 4.330

4. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.

Authors: Pedro C Rodriguez; Roberto Torres-Moya; Gil Reyes; Claudino Molinero; Dinorah Prada; Ana M Lopez; Isabel M Hernandez; Maria V Hernandez; Jose P Martinez; Xochel Hernandez; Angel Casaco; Mayra Ramos; Yisel Avila; Yinet Barrese; Enrique Montero; Patricia Hernandez
Journal: Results Immunol Date: 2012-11-21

CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior t1 MAb a possible new approach to treat this disease.

1. CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction.

2. Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab).

3. The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.

4. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.

5. A ligand for CD5 is CD5.

Review 6. Control of advanced cancer: the road to chronicity.

7. Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases.

8. Genetic polymorphisms of cell adhesion molecules in Behcet's disease in a Chinese Han population.

9. CD6 monoclonal antibodies differ in epitope, kinetics and mechanism of action.